


	Home \| Data & Statistics \| Collaborations \| Work with Us \| Publications \| About \| Links

Benchmarks for Cancers by Indication for Examination for 401,572 Diagnostic Mammography Examinations from 2002 - 2006 --- based on BCSC data as of 2009^*

You are viewing the 2009 collection of this data. Data from other times are also available:

2007

	Work-Up of Abnormal Screening Examination	Short-Interval Follow-Up	Evaluation of Breast Problem/ No Lump or Lump Unknown	Evaluation of Breast Problem/ Palpable Lump	All Diagnostic Examinations
Sensitivity^**	90.3	59.0	76.1	88.7	84.4
Readers with 5+ cancers	155	24	48	96	272
True Positives^†	3,871	220	1,152	2,056	9,529
Cancers^‡	4,289	373	1,513	2,317	11,295
Sensitivity (Median-50th percentile)	91.4	63.1	80.2	90.0	85.3
Sensitivity (25th, 75th percentiles)	85.7, 95.2	45.8, 70.3	71.1, 87.8	82.6, 93.1	78.3, 90.9
Sensitivity (10th, 90th percentiles)	78.9, 100	40, 73.3	58.1, 95.4	70, 97.8	70, 94.3
Specificity^§	87.9	96.5	94.9	88.7	91.9
Readers with 100+ non-cancers	261	180	147	115	381
True Negatives^\|\|	98,042	66,009	78,341	31,137	308,607
Non-cancers^#	111,535	68,433	82,526	35,092	335,684
Specificity (Median-50th percentile)	89.1	96.7	95.3	89.2	92.4
Specificity (25th, 75th percentiles)	84.3, 92.4	95, 98.1	92.3, 97.2	87, 94	89.4, 94.8
Specificity (10th, 90th percentiles)	79.3, 94.5	92.8, 98.9	90.4, 98.1	81.7, 95.6	86.3, 96.5

Notes

Numbers are frequencies unless otherwise indicated.

The first non-zero assessment within 90 days was used as the final assessment for analysis.

^* Includes examinations for radiologists with minimum numbers of cases in a given column as designated; excludes examinations for which the radiologist is unknown.

^** Sensitivity = the percentage of cancers that had an abnormal final interpretation (BI-RADS category 4 or 5 -- categories 0 or 3 with a recommendation for biopsy were recoded as 4).

^† True Positive = the number of cancers that had an abnormal final interpretation (BI-RADS category 4 or 5 -- categories 0 or 3 with a recommendation for biopsy were recoded as 4).

^‡ Cancers = the number of examinations with a tissue diagnosis of cancer within 1 year following the examination.

^§ Specificity = the percentage of non-cancers that had a negative final interpretation (BI-RADS category 1, 2, or 3 -- category 0 with no recommendation for biopsy nor additional imaging/workup were recoded as 3, while category 3 with recommendation for biopsy was recoded as 4).

^|| True Negative = the number of non-cancers that had a negative final interpretation (BI-RADS category 1, 2, or 3 -- category 0 with no recommendation for biopsy nor additional imaging/workup were recoded as 3, while category 3 with recommendation for biopsy was recoded as 4).

^# Non-cancers = the number of examinations without a tissue diagnosis of cancer within 1 year following the examination.

Table numbers last updated December 27, 2009. The following source must be cited when reproducing this table: NCI-funded Breast Cancer Surveillance Consortium co-operative agreement (U01CA63740, U01CA86076, U01CA86082, U01CA63736, U01CA70013, U01CA69976, U01CA63731, U01CA70040). Downloaded xx/xx/xxxx from the Breast Cancer Surveillance Consortium Web site - http://breastscreening.cancer.gov/data/benchmarks/diagnostic/2009/table7.html

[Return to Performance Benchmarks for Diagnostic Mammography]

Maintained by the Applied Research Program,
Division of Cancer Control and Population Sciences

Benchmarks for Cancers by Indication for Examination for 401,572 Diagnostic Mammography Examinations from 2002 - 2006 --- based on BCSC data as of 2009*

Notes

Benchmarks for Cancers by Indication for Examination for 401,572 Diagnostic Mammography Examinations from 2002 - 2006 --- based on BCSC data as of 2009^*